- Conditions
- Eating Disorders, Hypoestrogenemia
- Interventions
- 17-β estradiol transdermal patches, Placebo Patch, Micronized progesterone 200 MG, Placebo Pill.
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 35 Years · Female only
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 138
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bone Strength, Bone Density, FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- transdermal 17β-E2 with cyclic progestin, oral 17β-E2 with cyclic progestin, transdermal EE+LNG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Charlottesville, Virginia
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
- Interventions
- testosterone, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 528
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Interventions
- Exemestane, Exemestane and tamoxifen
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, letrozole
- Biological · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Leiomyoma
- Interventions
- CDB-2914
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 33 Years to 50 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Neoplasms
- Interventions
- Dexamethasone, Trabectedin
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 21
- States / cities
- Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
- Conditions
- Coronary Heart Disease
- Interventions
- Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years to 75 Years · Female only
- Enrollment
- 2,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2001
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumors, Advanced Cancer
- Interventions
- Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
- Drug · Procedure · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Imatinib Mesylate, Letrozole
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anorexia Nervosa
- Interventions
- Transdermal estrogen, Placebos
- Drug
- Lead sponsor
- Pouneh K. Fazeli, MD
- Other
- Eligibility
- 19 Years to 45 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Infertility, Female
- Interventions
- FET Protocol
- Other
- Lead sponsor
- Reproductive Medicine Associates of New Jersey
- Other
- Eligibility
- 18 Years to 53 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Basking Ridge, New Jersey • Marlton, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Lifestyle intervention, Mail-based
- Behavioral
- Lead sponsor
- Ontario Clinical Oncology Group (OCOG)
- Other
- Eligibility
- Female only
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 4
- States / cities
- Torrance, California • Boston, Massachusetts • Seattle, Washington
- Conditions
- Menopausal Syndrome
- Interventions
- Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18
- Biological · Drug · Other + 2 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 35 Years to 80 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Neoplasms
- Interventions
- pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
- Conditions
- Exercise-related Amenorrhea
- Interventions
- Transdermal 17Beta-estradiol, progesterone, Ethinyl Estradiol + Desogestrel, Sham Comparator
- Drug · Dietary Supplement
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 21 Years · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- letrozole, conventional surgery
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
- Interventions
- 17beta Estradiol, Transdermal placebo patch, Progesterone, Placebo Pill
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 386
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Estriol, Placebo, Copaxone
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
- Interventions
- PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more